Education
About Us
Working with TipRanks
Follow Us
Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
RESEARCH TOOLSreports
MNPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.72 - $54.30
Previous CloseN/A
Volume23.12K
Average Volume (3M)35.74K
Market Cap
$183.38M
Enterprise Value$27.22M
Total Cash (Recent Filing)-$2.01M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.55
Next Earnings
May 08, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.12
Shares Outstanding6,112,593
10 Day Avg. Volume31,092
30 Day Avg. Volume35,737
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-49.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$52.00Price Target Upside73.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Monopar Therapeutics Inc News
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentALXN-1840 is considered a derisked drug for the treatment of Wilson's disease and a commercial launch would provide revenue to fund the development of their radiopharmaceutical.
Market PotentialThe total addressable market for ALXN1840 could reach $420M in the U.S. alone.
Strategic PartnershipsMonopar Therapeutics announced a strategic agreement with Alexion, AstraZeneca Rare Disease, for the exclusive worldwide in-licensing of ALXN-1840 for the treatment of Wilson's disease.
Bears Say
Financial PerformanceThe company reported no revenues and a net loss of $4.11 per share, which is significantly higher than consensus estimated net loss of $1.29 per share.
Investor FocusInvestors are expected to be more focused on later-stage ALXN-1840 and anticipate incremental updates from MNPR-101-Lu to have a muted impact on share price in the near term.
Regulatory ChallengesProviding proof of fecal excretion of copper might require an additional study, posing a potential regulatory hurdle for ALXN1840's approval.
---
Ownership Overview
16.92% Insiders
0.43% Mutual Funds
20.42% Other Institutional Investors
61.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MNPR FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $1.72 and its highest was $54.30 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Monopar Therapeutics Inc’s market cap is $183.38M.
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s upcoming earnings report date is May 08, 2025 which is in 31 days.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on Mar 31, 2025. The company reported -$2.74 earnings per share for the quarter, missing the consensus estimate of -$0.47 by -$2.27.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate is -0.36.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 6,112,593 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -$2.74 in its last earnings report, missing expectations of -$0.47. Following the earnings report the stock price went down -9.72%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Currently, no hedge funds are holding shares in MNPR
---
Monopar Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.00 (73.33% Upside)
$52.00 (73.33% Upside)
Blogger Sentiment
Neutral
MNPR Sentiment 50%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
839.84%
12-Months-Change
Fundamentals
Return on Equity
-51.42%
Trailing 12-Months
Asset Growth
720.83%
Trailing 12-Months
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
---
MNPR Stock 12 Month Forecast
Average Price Target
$52.00
▲(73.33% Upside)
Technical Analysis
Xoma
―
Cidara Therapeutics
―
Annexon Biosciences
―
iTeos Therapeutics
―
Compass Therapeutics
―
Best Analysts Covering MNPR
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
+127.63%
reiterated a buy rating 6 days ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +127.63% per trade.
---